Wood's $498,000 purchase through a trust vehicle expands his beneficial stake to 338,103 shares as the medical robotics firm ...

PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported ...

Price targets for PROCEPT BioRobotics have been reset closer to its revised fair value, with many now clustered in the low to ...

PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members ...

PROCEPT BioRobotics (NASDAQ:PRCT) is preparing to release its quarterly earnings on Tuesday, 2026-02-24. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

PROCEPT BioRobotics (PRCT) stock gains as the company's Q2 2026 results beat estimates while Wells Fargo downgrades it on outlook. Read more here.

META: $214.48 million (5.3% of AUM) GOOGL: $171.23 million (4.2% of AUM) AMZN: $161.25 million (4.0% of AUM) NVDA: $149.51 million (3.7% of AUM) V: $137.50 million (3.4% of AUM) As of October 21, 2025 ...

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.35 per share a year ago.

Waters stated, “We now expect full year 2025 total revenue to be approximately $325.5 million, representing growth of approximately 45% compared to 2024.” System sales guidance for the U.S. remains at ...

On Thursday, Spruce Point Capital released a detailed report on PROCEPT BioRobotics (NASDAQ:PRCT), raising concerns about the claims surrounding its market potential and growth prospects, suggesting ...